Indaptus shares jump after announcing plans to test cancer treatment in a Phase 1 clinical trial

Shares of Indaptus Therapeutics Inc. /zigman2/quotes/204811863/composite INDP +14.94% were up 21.6% in premarket trading on Thursday after the company said U.S. regulators have allowed a Phase 1 clinical trial for its experimental cancer treatment to move forward. Indaptus plans to enroll patients with advanced solid tumors who have already unsucessfully undergone approved treatments. The study is set to begin in the second half of the year. Indaptus stock has tumbled 56.1% this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.12% has declined 17.7%.

/zigman2/quotes/204811863/composite

Add to watchlist INDP

Indaptus Therapeutics Inc.

US : U.S.: Nasdaq

$ 3.00

+0.39 +14.94%

Volume: 129,180

July 1, 2022 1:21p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$21.55 million

Rev. per Employee

N/A

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

3,781.02

-4.36 -0.12%

Volume: 1.13B

July 1, 2022 1:29p